Treatment of Mild Nondisseminated Pulmonary Nocardiosis in Immunocompetent Patients with Chronic Pulmonary Disease
This protocol covers mild, nondisseminated pulmonary nocardiosis in an immunocompetent patient with underlying chronic pulmonary disease and no evidence of disseminated infection.
Patients with mild nocardiosis typically have a chronic course leading to diagnosis and are often managed in the outpatient setting. No validated severity grading system exists for nocardiosis, but nondisseminated disease defines this lower-acuity group. In immunocompetent individuals with chronic pulmonary disease, close monitoring while susceptibility results are pending is feasible and appropriate.
For mild infection without dissemination, a single-antibiotic (monotherapy) approach — using an agent highly likely to be active — is the foundation of management. The specific antibiotic selection, complete dosing strategy, monitoring requirements, and treatment duration are detailed in the structured regimen.
Success is defined by clinical improvement of pulmonary nocardiosis and a demonstrable radiographic response on follow-up chest imaging.
References
DOI: 10.1093/cid/ciae643
- Although no validated grading system for Nocardia severity exists, patients with mild nocardiosis are often managed in the outpatient setting, have a chronic course leading to diagnosis, and have nondisseminated infection.
- Additionally, select immunocompetent patients with mild pulmonary nocardiosis (typically those with chronic pulmonary disease) can be closely monitored until susceptibility results are available.
- Conversely, those with mild infection can start with a single antibiotic that is highly likely to be an active agent.
- If combination therapy is started empirically, treatment can be narrowed to monotherapy, particularly if there are signs of clinical improvement.
- Patients with pulmonary or CNS disease should undergo follow-up chest or brain imaging, respectively, to evaluate for response to treatment.